Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (201-210 of 221) with videos related to

Pageof 23
Sort By:
Cancer Research|December 18, 2004
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaMohamed Bentires-Alj, J Guillermo Paez, Frank S David, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic ProfilingAlexa B Schrock, Shuyu D Li, Garrett M Frampton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Cancer Discovery|September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsHaiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Cancer|August 26, 2025
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024Narjust Florez, Sandip Patel, Heather A Wakelee, et al.
Lung Cancer (Amsterdam, Netherlands)|November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
Pageof 23

Showing results (201-210 of 221) with videos related to

Sort By:
Pageof 23
Cancer Research|December 18, 2004
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaMohamed Bentires-Alj, J Guillermo Paez, Frank S David, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic ProfilingAlexa B Schrock, Shuyu D Li, Garrett M Frampton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Cancer Discovery|September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsHaiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Cancer|August 26, 2025
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024Narjust Florez, Sandip Patel, Heather A Wakelee, et al.
Lung Cancer (Amsterdam, Netherlands)|November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
Pageof 23